Ticker News
$CDT News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
CDT: Shares outstanding 13,693,866 after recent issuances; Nasdaq deficiencies cleared
CDT Equity says recent share issuances and exercises of pre-funded warrants resulted in 13,693,866 shares outstanding as of August 31, 2026, and that it no longer has any Nasdaq listing deficiencies. The release does not disclose offering size, pricing, placement agents, or gross proceeds, so the exact cash raised and incremental dilution versus the prior cap table are not specified. Timing: Same-day dilution is possible, but the press release does not provide a firm first-dilution date.
CDT validates patent-backed enhanced solid forms and files patents to advance assets
CDT (NASDAQ: CDT) announced new solid forms/alternative crystal structures for existing drug compounds that the company says show improved stability, solubility and manufacturability and have been protected under its Substance of Matter IP. The company filed patents, used AI to identify new potential uses (targeting underserved diseases), and will move the findings into lab models to build experimental evidence ahead of partnering and out-license discussions.
CDT invests in Pep’d via SAFE with $10M valuation cap
CDT Equity (NASDAQ: CDT) entered into a SAFE with Pep’d Inc. that will automatically convert into Safe Preferred Stock upon Pep’d closing an equity financing, subject to a $10 million valuation cap. CDT says the deal gives it capital-efficient exposure to the growing US peptide market and to Pep’d's AI-enabled, telehealth-integrated peptide platform, which has launched and begun generating revenue. Pep’d is controlled by CDT CEO Dr. Andrew Regan, creating a potential conflict of interest, and the release does not disclose the SAFE amount or timing of conversion.
CDT highlights Sarborg's quantum-assisted coformer selection for solid-form development
CDT flagged Sarborg's expansion of its Signature Intelligence platform into quantum-assisted coformer selection via SarborgQ, combining proprietary datasets, agentic AI and emerging quantum computing to accelerate solid-form work. Sarborg says it has a curated database of >850 coformers and intends to deploy the tools to identify new co-crystal/salt opportunities, create patentable assets across its IP portfolio and offer the capability to external partners, though no validation data or timelines were disclosed.